• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Pre-Market Session

    2/9/24 8:06:11 AM ET
    $BTAI
    $CRVS
    $DSGN
    $EVOK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BTAI alert in real time by email

    Gainers

    • NanoString Technologies (NASDAQ:NSTG) stock moved upwards by 26.9% to $0.15 during Friday's pre-market session. The company's market cap stands at $7.0 million.
    • TC BioPharm (Holdings) (NASDAQ:TCBP) stock rose 21.81% to $1.34.
    • OKYO Pharma (NASDAQ:OKYO) stock increased by 21.32% to $1.74. The company's market cap stands at $57.6 million.
    • Corvus Pharma (NASDAQ:CRVS) shares moved upwards by 20.5% to $2.41. The market value of their outstanding shares is at $118.1 million.
    • CytoMed Therapeutics (NASDAQ:GDTC) stock rose 14.28% to $2.56. The market value of their outstanding shares is at $29.5 million.
    • Ontrak (NASDAQ:OTRK) stock increased by 11.76% to $0.19. The company's market cap stands at $5.2 million.

    Losers

    • Synlogic (NASDAQ:SYBX) shares decreased by 52.2% to $1.65 during Friday's pre-market session. The company's market cap stands at $15.1 million.
    • BioXcel Therapeutics (NASDAQ:BTAI) shares decreased by 35.47% to $2.42. The market value of their outstanding shares is at $72.4 million.
    • Evoke Pharma (NASDAQ:EVOK) stock declined by 19.07% to $0.52. The company's market cap stands at $1.7 million.
    • Syra Health (NASDAQ:SYRA) stock declined by 16.71% to $4.04. The company's market cap stands at $25.9 million.
    • Inspire Veterinary (NASDAQ:IVP) shares fell 12.08% to $0.12. The market value of their outstanding shares is at $2.9 million.
    • Design Therapeutics (NASDAQ:DSGN) stock fell 11.36% to $2.03. The company's market cap stands at $113.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BTAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BTAI
    $CRVS
    $DSGN
    $EVOK

    CompanyDatePrice TargetRatingAnalyst
    OKYO Pharma Limited
    $OKYO
    2/20/2026$7.00Overweight
    Piper Sandler
    Design Therapeutics Inc.
    $DSGN
    1/7/2026$18.00Outperform
    Oppenheimer
    OKYO Pharma Limited
    $OKYO
    12/8/2025$5.00Buy
    B. Riley Securities
    Design Therapeutics Inc.
    $DSGN
    12/3/2025$14.00Market Perform → Outperform
    Leerink Partners
    Design Therapeutics Inc.
    $DSGN
    12/3/2025$15.00Buy
    Craig Hallum
    Design Therapeutics Inc.
    $DSGN
    11/20/2025$13.00Sector Perform → Outperform
    RBC Capital Mkts
    Corvus Pharmaceuticals Inc.
    $CRVS
    10/13/2025$16.00Overweight
    Barclays
    Corvus Pharmaceuticals Inc.
    $CRVS
    1/2/2025$11.00Buy
    H.C. Wainwright
    More analyst ratings

    $BTAI
    $CRVS
    $DSGN
    $EVOK
    SEC Filings

    View All

    SEC Form 6-K filed by OKYO Pharma Limited

    6-K - OKYO Pharma Ltd (0001849296) (Filer)

    2/23/26 11:00:27 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by OKYO Pharma Limited

    SCHEDULE 13G - OKYO Pharma Ltd (0001849296) (Subject)

    2/18/26 5:42:07 PM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Design Therapeutics Inc.

    SCHEDULE 13G/A - Design Therapeutics, Inc. (0001807120) (Subject)

    2/17/26 4:27:23 PM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTAI
    $CRVS
    $DSGN
    $EVOK
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for IGALMI issued to BIOXCEL THERAPEUTICS, INC.

    Submission status for BIOXCEL THERAPEUTICS, INC.'s drug IGALMI (ORIG-1) with active ingredient DEXMEDETOMIDINE has changed to 'Approval' on 04/05/2022. Application Category: NDA, Application Number: 215390, Application Classification: Type 3 - New Dosage Form

    4/6/22 2:18:32 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for GIMOTI

    Submission status for EVOKE PHARMA INC's drug GIMOTI (SUPPL-1) with active ingredient METOCLOPRAMIDE HYDROCHLORIDE has changed to 'Approval' on 01/14/2021. Application Category: NDA, Application Number: 209388, Application Classification: Labeling

    1/15/21 5:10:35 AM ET
    $EVOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTAI
    $CRVS
    $DSGN
    $EVOK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO and COO Prasad Priya bought $13,257 worth of shares (14,448 units at $0.92) and sold $10,144 worth of shares (4,153 units at $2.44) (SEC Form 4)

    4 - Syra Health Corp (0001922335) (Issuer)

    9/13/24 9:10:53 AM ET
    $SYRA
    Diversified Commercial Services
    Consumer Discretionary

    Jones William Benton bought $34,624 worth of shares (20,000 units at $1.73), increasing direct ownership by 15% to 153,773 units (SEC Form 4)

    4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

    5/7/24 5:06:34 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Miller Richard A Md bought $1,000,000 worth of shares (577,634 units at $1.73) (SEC Form 4)

    4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

    5/7/24 5:05:52 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTAI
    $CRVS
    $DSGN
    $EVOK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $BTAI
    $CRVS
    $DSGN
    $EVOK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CEO Alexander Gregory R. was granted 110,537 units of Restricted Stock Units (SEC Form 4)

    4 - Syra Health Corp (0001922335) (Issuer)

    2/3/26 4:30:22 PM ET
    $SYRA
    Diversified Commercial Services
    Consumer Discretionary

    Director Thompson Peter A. exercised 210,000 shares at a strike of $5.33 (SEC Form 4)

    4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

    1/30/26 6:39:04 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Alexander Gregory R.

    3 - Syra Health Corp (0001922335) (Issuer)

    1/14/26 5:05:31 PM ET
    $SYRA
    Diversified Commercial Services
    Consumer Discretionary

    Piper Sandler initiated coverage on OKYO Pharma with a new price target

    Piper Sandler initiated coverage of OKYO Pharma with a rating of Overweight and set a new price target of $7.00

    2/20/26 8:25:04 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Oppenheimer initiated coverage on Design Therapeutics with a new price target

    Oppenheimer initiated coverage of Design Therapeutics with a rating of Outperform and set a new price target of $18.00

    1/7/26 9:09:56 AM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on OKYO Pharma with a new price target

    B. Riley Securities initiated coverage of OKYO Pharma with a rating of Buy and set a new price target of $5.00

    12/8/25 8:35:27 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BTAI
    $CRVS
    $DSGN
    $EVOK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

    SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at Oppenheimer 36th Annual Healthcare Life Sciences Conference which is being held virtually. The presentation will be on Thursday, February 26, 2026 at 2:40pm ET. A webcast of the presentation will be available live and for 90 days following the event. The webcast may be accessed via the investor relations section of the Corvus website. About Corvus Pharmaceuticals Corvus Pharmaceuticals is a clinical-stage

    2/23/26 4:01:00 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress

    LONDON and NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that its abstract has been accepted for presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting, taking place May 3-7, 2026, in Denver, Colorado. Chief Scientific Officer Raj Patil, Ph.D., will share the data in a presentation titled: "First-in-Human Study of Urcosimod to Treat Neuropathic Corneal Pain (NCP) Shows Clinically Meaningful Pain Reduction and Quality-of-Life Improve

    2/23/26 11:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer's Dementia

    Discussion will focus on the high unmet need and the lack of FDA-approved treatment options associated with acute agitation episodes in Alzheimer's dementia Large patient population affected by Alzheimer's agitation, with approximately ~100 million annual episodes1 KOL Roundtable to be held on Friday, February 27, at 2:00 p.m. EST NEW HAVEN, Conn., Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today announced it will host a virtual key opinion leader (KOL) roundtable on Friday, February 27, from 2:00 to 3:00 p.m. EST. The event is a cont

    2/19/26 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTAI
    $CRVS
    $DSGN
    $EVOK
    Financials

    Live finance-specific insights

    View All

    Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

    Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following longer 8-week treatment  75% of soquelitinib patients achieved EASI 75, 25% achieved EASI 90 and 33% achieved IGA 0/1 Cohort 1-4 have demonstrated positive safety and efficacy results in patients who have received prior systemic therapy including patients who are treatment resistant Company to host conference call and webcast today at 8:00 am ET / 5:00 am PT SOUTH SAN FRANCISCO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, announced positive results from cohort 4 of the randomized,

    1/20/26 7:00:00 AM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

    SOUTH SAN FRANCISCO, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, announced that it will host a conference call and webcast on Tuesday, January 20, 2026 at 8:00 am ET (5:00 am PT) to report the results from cohort 4 of the randomized, blinded, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. Conference Call, Webcast and Presentation SlidesThe conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live we

    1/16/26 4:01:00 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OKYO Pharma Announces Chairman and Founder Acquires Shares

    LONDON and NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman, has a beneficial interest, has acquired 24,551 of the Company's ordinary shares on NASDAQ, bringing his total holding to 10,516,297 shares. About Urcosimod (Formerly called OK-101)Urcosimod is a lipid conjugated chemerin peptide agonist

    12/15/25 8:30:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BTAI
    $CRVS
    $DSGN
    $EVOK
    Leadership Updates

    Live Leadership Updates

    View All

    OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer

    Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in corneal diseaseDr. Mantelli will lead the clinical and regulatory strategy to advance the company's development program in neuropathic corneal pain (NCP), leveraging urcosimod's FDA Fast Track designationThis appointment, following the recent CEO appointment, further strengthens OKYO's world-class ophthalmology leadership team LONDON and NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neur

    2/10/26 8:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting

    Mark Pavao to Join BioXcel Therapeutics as Interim Chief Commercial Officer Mr. Pavao Brings Deep Experience in Neuroscience Sales and Marketing to Support Potential Launch of IGALMI® in At-Home Setting as Early as Year-End 2026 BioXcel Therapeutics on Track to Submit a sNDA for IGALMI® this Month NEW HAVEN, Conn., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today announced the advancement of its commercial planning for IGALMI® in the at-home setting. As part of this, Mark Pavao, a commercial planning and launch advisor with more than 3

    1/12/26 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer

    Accomplished industry leader Robert J. Dempsey brings extensive commercialization and ophthalmic expertise Gary S. Jacob, Ph.D., will transition to Chief Development Officer and continue to serve on the Board LONDON and NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory eye diseases, announces that, effective immediately, Robert J. Dempsey will assume the role of Chief Executive Officer. Gary S. Jacob, Ph.D. will transition to Chief Development Officer and

    1/5/26 7:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BTAI
    $CRVS
    $DSGN
    $EVOK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by TC BioPharm (Holdings) plc

    SC 13G/A - TC BioPharm (Holdings) plc (0001872812) (Subject)

    11/14/24 4:41:42 PM ET
    $TCBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Synlogic Inc.

    SC 13G/A - SYNLOGIC, INC. (0001527599) (Subject)

    11/14/24 4:40:57 PM ET
    $SYBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ontrak Inc.

    SC 13G/A - Ontrak, Inc. (0001136174) (Subject)

    11/14/24 4:24:03 PM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care